Cepheid Pipeline Update Focuses on Tests for CT/NG, Cancer, TB | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid this week updated its test pipeline with a focus on gonorrhea and chlamydia, cancer, and tuberculosis over the next few years.

Speaking at two investor conferences, Cepheid CEO John Bishop outlined his company's plans to expand its testing menu through 2017, when if all goes according to plans, the company would have a total of 42 tests available globally.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.